Galderma has presented new data on Nemluvio showing responses in patients with atopic dermatitis aged 12 and older, extending the clinical picture of the interleukin-31 receptor antagonist into the adolescent population.

The presentation, reported by TradingView, centers on Nemluvio's demonstrated responses in atopic dermatitis patients aged 12 years and above. Galderma did not stop at its established adult indication: the new analyses cover the 12-and-older cohort that dermatologists manage routinely in moderate-to-severe disease.

What does the new dataset add?

Atopic dermatitis treatment in adolescents has long relied on agents studied predominantly in adults, with pediatric extrapolation a recurring concern in clinic. Data that specifically document responses in patients aged 12 and older give prescribers a more direct evidence anchor for this age group.

Nemluvio targets the IL-31 pathway, a mechanism associated with pruritus in atopic dermatitis. Galderma's latest presentation adds to the program's dataset by reporting responses across the 12-and-older population.

Why the age threshold matters

The 12-year cutoff is a familiar regulatory boundary in dermatology. Several systemic therapies for atopic dermatitis carry indications that begin at this age, and payers frequently frame coverage policies around it.

For Galderma, presenting response data in patients aged 12 and older positions Nemluvio within that established framework rather than requiring clinicians to reason from adult data alone.

What dermatologists should watch next

Full study details — endpoints, effect sizes, and cohort composition — will determine how the new analyses fit into the broader Nemluvio evidence base. Clinicians will want to see the primary outcome measures and the durability of responses as the data move from presentation to peer-reviewed publication.

Galderma's continued investment in Nemluvio's atopic dermatitis program suggests further data readouts and label-relevant analyses are likely as the company builds the case for the IL-31 inhibitor across the adolescent and adult treatment spectrum.